Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Mar 9;24(1):48.
doi: 10.1186/s12882-023-03091-8.

Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report

Affiliations
Case Reports

Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report

Kenta Tominaga et al. BMC Nephrol. .

Abstract

Background: Immune checkpoint inhibitors (ICIs) have provided significant benefits in cancer treatment, but they could develop immune-related adverse events (irAE). ICI-associated renal adverse effects are rare and tubulointerstitial nephritis (TIN) is the most common in the renal irAE. However, only a few case reports of renal vasculitis associated with ICI have been reported. In addition, the characteristics of infiltrating inflammatory cells of ICI-associated TIN and renal vasculitis have been uncertain.

Case presentation: A 65-year-old man received immune checkpoint inhibitors (ICIs), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (programmed cell death 1) antibodies for aggravated metastatic malignant melanoma. About 1 week after the second administration of nivolumab and ipilimumab, acute kidney injury developed. A renal biopsy was performed that showed TIN and non-necrotizing granulomatous vasculitis in interlobular arteries. Massive CD3+ T cells and CD163+ macrophages infiltrated both tubulointerstitium and interlobular arteries. Many infiltrating cells tested positive for Ki-67 and PD-1 ligand (PD-L1), but negative for PD-1. In CD3+ T cells, CD8+ T cells were predominantly infiltrated, and these cells were positive for Granzyme B (GrB) and cytotoxic granule TIA-1, but negative for CD25, indicating antigen-independent activated CD8+ T cells. Infiltration of CD4+ T cells was noted without obvious CD4+ CD25+ regulatory T (Treg) cells. His renal dysfunction recovered within 2 months of treatment with prednisolone in addition to discontinuation of nivolumab and ipilimumab.

Conclusions: We herein reported a case of ICI-related TIN and renal granulomatous vasculitis with infiltration of massive antigen-independent activated CD8+ T cells and CD163+ macrophages, and none or few CD4+ CD25+ Treg cells. These infiltrating cells might be a characteristic of the development of renal irAE.

Keywords: Acute kidney injury; Granulomatous vasculitis; Immune checkpoint inhibitor; Immune-related adverse event; Tubulointerstitial nephritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Tubulointerstitial nephritis and granulomatous vasculitis. (A) Tubulointerstitial nephritis developed with focal but extensive infiltration of inflammatory cells in the tubulointerstitium. (B) Tubulointerstitial nephritis was noted, but glomerular lesions could not be seen. (C) Mononuclear cells including eosinophils (arrowhead) infiltrated the interstitium with mild tubulitis (arrow). (D, E) Non-necrotizing and granulomatous vasculitis developed in interlobular arteries. (F) Infiltration of mononuclear inflammatory cells were found in arterial intima, arterial media (arrowhead), and the arterial adventitia to the perivascular area without fibrinoid necrosis, indicating non-necrotizing and granulomatous arteritis. (A-C) HE stain; (D-F) PAM stain; (A) × 100, (B) × 200; (C, F) × 1,000; (D, E) × 400
Fig. 2
Fig. 2
Characteristics of inflammatory cells in the granulomatous arteritis and tubulointerstitial nephritis. In renal granulomatous vasculitis (A-J), many CD3+ T cells (A) and CD163+ macrophages (B) infiltrated the arterial intima, media, and adventitia up to around the interlobular artery. Many infiltrative inflammatory cells were positive for Ki67 (C), indicating that infiltrating cells were proliferating in the vasculitis lesion. (D, E) Inflammatory cells were PD-1 negative and PD-L1 positive. (F, G) In CD3+ cells, abundant CD8+ T cells and less predominantly CD4+ T cells were noted. (H) Only a few CD25+ cells (arrowhead) were detected, however almost all cells were negative for CD25. Infiltrating cells were positive for granzyme B (GrB) (arrow in I) and cytotoxic granule T cell intracellular antigen 1 (TIA-1) (J), indicating effector and cytotoxic T cells. In tubulointerstitial nephritis (K-O), a similar phenotype of infiltrating cells, such as CD3+ T cells (K), predominantly CD8+ T cells (L), without CD25 expression (M), but positive for TIA-1 (N) were noted in interstitium. (O) Many CD163+ macrophages were also evident in intersitium. (A-G, K-M, O) × 200; (H-J, N) × 400

References

    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/NEJMoa1504030. - DOI - PMC - PubMed
    1. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi: 10.1158/2159-8290.CD-18-0367. - DOI - PubMed
    1. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574. doi: 10.1093/annonc/mdv623. - DOI - PubMed
    1. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647. doi: 10.1016/j.kint.2016.04.008. - DOI - PMC - PubMed
    1. Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–446. doi: 10.1681/ASN.2019070676. - DOI - PMC - PubMed

Publication types

MeSH terms